Last reviewed · How we verify
NCT06883409
Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer
NA trial testing Interval Cytoreduction Surgery in Ovarian Neoplasms in 33 participants. Currently enrolling.
14 June 2024
Quick facts
| Lead sponsor | Instituto Nacional de Cancerologia de Mexico |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 33 |
| Start date | 19 May 2022 |
| Primary completion | 14 June 2024 |
| Estimated completion | 30 December 2025 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Interval Cytoreduction Surgery
Conditions studied
- Ovarian Neoplasms — all drugs for Ovarian Neoplasms →
Sponsor
Instituto Nacional de Cancerologia de Mexico — full company profile →
Who can join
Adults 18 to 80, female only, with Ovarian Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a study that aims to demonstrate the non-inferiority of minimally invasive surgery versus open surgery, as an approach for patients with advanced ovarian cancer who received neoadjuvant chemotherapy, giving them the benefits of laparoscopic surgery. This way they can continue with their complementary treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Minimally invasive surgery in gynecologic oncology: a narrative review of controversies and clinical implications.
Ayoub NL, Shin R, Tseng J, Francoeur AA. · · 2025 · PMID 42211936 · DOI 10.21037/gpm-25-19
Verify or expand the search:
- PubMed search for NCT06883409
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Neoplasms
Currently open trials in the same condition.
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07280312 — Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions · NA · recruiting
- NCT07038369 — A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · Phase 1 · active not recruiting
- NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
- NCT06751329 — A Study of DM002 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
Other Instituto Nacional de Cancerologia de Mexico trials
Trials by the same sponsor.
- NCT06422533 — Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients · NA · recruiting
- NCT06477302 — Scale of Therapeutic Adherence to Respiratory Rahabilitation for Lung Cancer · recruiting
- NCT06090747 — Improving Lifestyle Behavior by "Joven, Fuerte y Saludable" Multidisciplinary Program. · NA · recruiting
- NCT06238882 — Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. · NA · recruiting
- NCT05713006 — Alectinib Pharmacokinetic in Patients With NSCLC · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06883409 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto Nacional de Cancerologia de Mexico
- Last refreshed: 26 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06883409.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing